Abraxane, Nab-Paclitaxel, is Taxol® drug (chemotherapy) link to a protein called Albumin. As a monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Abraxane in combination with carboplatin is indicated for the first-line treatment of non small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
Home » Abraxane
Facebook
Twitter
LinkedIn
WhatsApp
Abraxane
To check if our service suits your case
We need to talk
Improve therapeutic outcomes, prolong life and quality of life, are our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.
Article categories
קטגוריות המאמרים
Popular topics
Tags
ASCO 2025
ASCO 2026
Biological Drugs
Breakthrough Therapy Designation
Breast Cancer Research
Breast Oncology
Cancer Research
Cancer Treatment
CAR T treatments
CDK4/6 Inhibitors
Chemotherapy
Clinical Trials
Daraxonrasib
EGFR MET inhibitor
Fulvestrant
Genetic Engineering Treatments
Genomic Testing
HNSCC
Immunotherapy
innowacyjne terapie onkologiczne
Keytruda
KRAS
leczenie nowotworów mózgu
leki biologiczne
Medical Cannabis
nadzieja dla pacjentów
Oncology
onkologia zaawansowana
OrigAMI-4
Pancreatic Cancer Research
Personalized Medicine
PFS
PIK3CA
Precision Medicine
Precision Oncology
Progression Free Survival
przerzuty do opon mózgowo-rdzeniowych
RAS(ON) Inhibitor
Rybrevant
Stage 4 Cancer
Stage IV Breast Cancer
Subcutaneous Injection
Targeted Drugs
Targeted Therapy
Trial-In Pharma






